Y Intercept Hong Kong Ltd Purchases Shares of 9,425 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Y Intercept Hong Kong Ltd purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,425 shares of the biopharmaceutical company’s stock, valued at approximately $9,908,000. Regeneron Pharmaceuticals accounts for about 0.6% of Y Intercept Hong Kong Ltd’s investment portfolio, making the stock its 12th biggest position.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Sachetta LLC grew its position in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares in the last quarter. Rakuten Securities Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares in the last quarter. Stephens Consulting LLC purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $26,000. FSA Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $26,000. Finally, Family Firm Inc. purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on REGN. Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Finally, Oppenheimer reduced their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,107.29.

Regeneron Pharmaceuticals Stock Up 1.3 %

NASDAQ REGN opened at $778.00 on Monday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $735.95 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The business’s 50-day moving average is $876.85 and its 200 day moving average is $1,011.88. The stock has a market capitalization of $85.49 billion, a PE ratio of 19.25, a PEG ratio of 3.00 and a beta of 0.08.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.